Search results for "New therapies"
Spotlight on novel therapies for type 1 diabetes
Manufacturer trials reported the effects of weekly insulin and teplizumab in patients with type 1 diabetes, while recent reviews looked at preventing beta-cell loss with various therapeutics and using drugs approved for type 2 diabetes to combat chronic kidney disease in type 1.
https://diabetes.acponline.org/archives/2023/11/10/5.htm
10 Nov 2023
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria
In a trial of more than 1,000 diabetic patients with proteinuria, adding an ACE inhibitor to an ARB didn't improve estimated glomerular filtration rate and increased risk for hyperkalemia and acute kidney injury, so the trial was halted early.
https://diabetes.acponline.org/archives/2014/05/09/6.htm
9 May 2014
Insulin/liraglutide combination effective in uncontrolled diabetes, study finds
Combination insulin degludec and liraglutide was noninferior to up-titration of glargine at reducing HbA1c in patients with uncontrolled type 2 diabetes in an industry-funded phase III trial.
https://diabetes.acponline.org/archives/2016/03/11/2.htm
11 Mar 2016
Safety of dipeptidyl peptidase-4 inhibitors analyzed in 2 studies
A meta-analysis of dipeptidyl peptidase-4 inhibitors showed no increase in pancreatic adverse events, while a trial of saxagliptin found no effect on the overall rate of cardiovascular events.
https://diabetes.acponline.org/archives/2014/02/14/7.htm
14 Feb 2014